comparemela.com

Latest Breaking News On - Yungjin pharm - Page 3 : comparemela.com

Global Spinal Stenosis Treatment Market Future Scope, Development, Revenue and Growth Factors up to 2027 | |Sumitomo Dainippon Pharma Co., Ltd, NIPPON SHINYAKU CO.,LTD, Taisho Pharmaceuticals Co., Ltd – KSU

9 Spinal stenosis treatment market­ is expected to grow at a substantial CAGR in the forecast period of 2020-2027. This rise in the market value can be attributed to the increasing number of product offerings for the treatment of spinal stenosis is fueling the market growth. The major players in the spinal stenosis treatment market­ are Mallinckrodt, Yungjin Pharm, Ono Pharmaceutical  Co.,  Ltd, Sumitomo Dainippon Pharma Co., Ltd, NIPPON SHINYAKU CO.,LTD, Taisho Pharmaceuticals Co., Ltd,  RTI Surgical Holdings, Inc, Medtronic, Johnson & Johnson Services, Inc, Empirical Spine, Inc, Yungjin Pharm.co,.Ltd, Alphatec Spine, Inc, B. Braun Melsungen AG, Exactech, Inc, Globus Medical Inc, NuVasive, Inc, Orthofix Holdings, Inc, Stryker, Zimmer Biomet, Pfizer Inc, Vertos Medical Inc, Endo Pharmaceuticals Inc, Vivex among others.

United-states
Pune
Maharashtra
India
American
B-braun-melsungen
Zimmer-biomet
Yungjin-pharm
America-europe
Empirical-spine-inc
Exactech-inc
Surgical-holdings-inc

Drug patent expiry in 2021: Opportunities and challenges in the Korean market

Drug patent expiry in 2021: Opportunities and challenges in the Korean market Min Son of Hanol IP & Law looks ahead at the key deadlines in the South Korean drug patent market for 2021 Sponsored by January 12 2021 With each new year, pharmaceutical companies are faced with the loss of exclusivity that accompanies the expiration of their patents, and by the same token, drug manufacturers are also afforded new opportunities and challenges due to the entry of generic competition. In South Korea, as many as 62 patents for 158 pharmaceutical products are supposed to expire this year, with more than half of these expected to potentially be launched as generics in the absence of any additional patents in the patent listing.

South-korea
Amgen-xgeva
Novarti-revolade
Arnuity-ellipta
Bayer-xarelto
Chong-kun-dang-bredinin
Janssen-stelara
Trelegy-ellipta
Astella-mycamine
Boehringer-ingelheim-pradaxa
Novarti-rydapt
Novarti-tykerb

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.